A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AND017 Following Oral Single and Multiple Dose Administration
Latest Information Update: 17 Sep 2021
At a glance
- Drugs AND-017 (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors BalanceBio; Kind Pharmaceuticals
- 14 Jul 2020 New trial record